Here is the complete patent application following the provided outline and incorporating the research paper's technical details:

# DESCRIPTION  

## FIELD OF THE INVENTION  

The present invention relates generally to noninvasive optical spectroscopy systems and methods for monitoring tissue metabolism and hemodynamics. More specifically, the invention pertains to a super-continuum infrared spectroscopy system for measuring cytochrome c oxidase (CCO) redox states along with oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) concentrations in biological tissues. The system finds particular utility in medical applications including but not limited to monitoring cerebral metabolism in traumatic brain injury, stroke diagnosis, concussion assessment, and evaluation of organ viability during hemorrhagic shock treatments.  

## BACKGROUND  

Current methods for monitoring cerebral and tissue metabolism suffer from significant limitations in clinical practice. Functional magnetic resonance imaging (fMRI) provides hemodynamic information but lacks metabolic specificity, requires expensive infrastructure, and cannot provide continuous monitoring. Near-infrared spectroscopy (NIRS) systems measure hemoglobin oxygenation but cannot directly assess cellular metabolic activity. Existing optical techniques for measuring cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain, have been hampered by insufficient signal-to-noise ratios due to the relatively weak absorption signature of CCO compared to hemoglobin.  

The clinical need for improved metabolic monitoring is particularly acute in trauma care, where hemorrhagic shock accounts for the majority of preventable trauma deaths. Current resuscitation strategies such as resuscitative endovascular balloon occlusion of the aorta (REBOA) lack real-time metabolic feedback to optimize treatment. Similarly, in neurological care, the inability to continuously monitor cerebral metabolism limits early detection of secondary brain injury following trauma or ischemia.  

Prior attempts to measure CCO noninvasively have used broadband lamp sources with limited brightness, resulting in marginal signal quality. These systems cannot reliably distinguish the small CCO signal from the stronger hemoglobin absorption and background tissue scattering. There exists an unmet need for a robust, portable system capable of simultaneously measuring both hemodynamic and metabolic parameters with sufficient sensitivity for clinical use.  

## SUMMARY OF THE INVENTION  

The present invention overcomes the limitations of prior systems through a super-continuum infrared spectroscopy of cytochrome c oxidase (SCISCCO) system that employs a high-brightness supercontinuum laser (SCL) source. The system provides simultaneous, noninvasive measurement of CCO redox states along with HbO and HbR concentrations with significantly improved signal-to-noise ratio compared to conventional approaches.  

Key aspects of the invention include:  

1. An all-fiber integrated supercontinuum laser source generating output from 670 nm to 2500 nm with time-averaged power up to 11 W, providing nearly an order of magnitude greater brightness than conventional lamp sources in the 750-900 nm range critical for CCO measurements.  

2. A differential measurement configuration employing a reference arm to compensate for source fluctuations and environmental noise, combined with lock-in detection to reject ambient light interference.  

3. A portable cart-based implementation integrating the laser source, optical system, detection electronics, and processing computer into a clinically deployable package.  

4. Algorithms based on modified Beer-Lambert law that extract chromophore concentrations from measured spectral changes using known extinction coefficients and differential pathlength factors.  

The system has been validated through human studies demonstrating simultaneous measurement of hemodynamic and metabolic responses during physiological challenges (blood pressure cuff occlusion, breath-holding) and cognitive tasks (attention tests). Animal studies in swine models of hemorrhagic shock have shown the system's ability to monitor cerebral metabolic changes during resuscitative interventions including partial REBOA and valproic acid administration.  

## DETAILED DESCRIPTION  

The SCISCCO system architecture comprises three primary subsystems: (1) the supercontinuum laser source, (2) the optical measurement apparatus, and (3) the signal processing and display components. Each subsystem is described in detail below.  

### Supercontinuum Laser Source  

The light source is a modulational instability-initiated supercontinuum laser (SCL) employing a master oscillator power amplifier (MOPA) configuration. A distributed feedback semiconductor seed laser generates ~1 ns pulses at 1060 nm with adjustable repetition rates from 100 kHz to 4 MHz. These pulses are amplified through a two-stage ytterbium-doped fiber amplifier system, with the first stage optimized for noise performance and the second stage designed to minimize nonlinear distortions through use of a cladding-pumped architecture.  

The amplified pulses are coupled into a cascade of nonlinear fibers for spectral broadening. Initial spectral broadening occurs in a few meters of standard single-mode fiber where modulational instability converts the nanosecond pulses into a train of picosecond pulses. These are then coupled into several meters of nonlinear photonic crystal fiber designed for supercontinuum generation across the near-infrared (NIR) and short-wave infrared (SWIR) bands.  

The resulting supercontinuum spans 670-2500 nm with time-averaged power scalable from 0.3 W to 11 W depending on repetition rate. The source maintains excellent spatial coherence with near-diffraction-limited beam quality across the entire output spectrum. All fiber components are fusion-spliced to ensure robustness, with the complete laser assembly occupying a compact 10"×14"×2.5" footprint.  

### Optical Measurement Apparatus  

The optical system employs a differential measurement configuration to maximize signal-to-noise ratio. Key components include:  

1. A tunable spectrometer (Acton 2150 with 600 g/mm grating) selecting specific wavelengths from the supercontinuum output.  

2. An optical chopper operating at 271 Hz to enable lock-in detection.  

3. A polarizer to maintain consistent polarization state and minimize polarization-dependent noise.  

4. A wedged window beam splitter dividing the beam into sample (99%) and reference (1%) arms.  

5. Fiber-optic probes for light delivery to and collection from the measurement site, with typical source-detector separations of 2-3 cm depending on application.  

6. Matched silicon photodetectors (DET100A) for both arms.  

7. Synchronized lock-in amplifiers (SR850) referenced to the chopper frequency.  

The reference arm provides real-time normalization to account for source intensity fluctuations. Lock-in detection rejects ambient light interference and improves signal-to-noise ratio by approximately two orders of magnitude compared to direct detection.  

### Signal Processing and Algorithms  

The system employs a modified Beer-Lambert law approach to extract chromophore concentrations from measured spectral changes. The algorithm solves the following equation for concentration changes Δc of HbO, HbR, and CCO:  

ln(I₀(λ)/Iₜ(λ)) = [ε_HbO(λ)Δc_HbO + ε_HbR(λ)Δc_HbR + ε_CCO(λ)Δc_CCO]·DPF·d + G(λ)  

Where:  
- I₀ and Iₜ are reference and measurement intensities  
- ε are wavelength-dependent extinction coefficients  
- DPF is the differential pathlength factor (6.26 for adult forehead)  
- d is source-detector separation (2-3 cm)  
- G(λ) accounts for scattering losses  

The system uses 47 wavelength points between 759-897 nm for the calculation. Extinction coefficients are taken from published literature, with the CCO spectrum verified through in vitro measurements of bovine heart CCO solutions in both oxidized and reduced states.  

### System Implementations  

The invention encompasses both laboratory and clinical implementations:  

1. **Laboratory Configuration**: A benchtop system with discrete optical components optimized for fundamental measurements and method development.  

2. **Cart-Based Clinical Prototype**: A portable three-level cart system integrating:  
   - Top level: SCL source and processing laptop  
   - Middle level: Optical hardware including spectrometer, beam delivery, and detection  
   - Bottom level: Electronics including lock-in amplifiers and power supplies  

The clinical prototype features a graphical user interface for parameter setting and real-time display of metabolic and hemodynamic parameters. The system has been validated for transport stability, maintaining performance after movement over brick flooring and transport via vehicle.  

### Measurement Protocols  

The system supports multiple measurement modalities:  

1. **Blood Pressure Testing**: Forearm measurement during cuff occlusion demonstrates system response to ischemia.  

2. **Breath-Holding Tests**: Forehead measurements during apneic periods show expected HbO increases and CCO decreases.  

3. **Cognitive Attention Tests**: Forehead monitoring during letter recognition tasks reveals frontal lobe activation patterns.  

4. **Hemorrhagic Shock Monitoring**: Continuous cerebral monitoring during swine experiments with partial REBOA and valproic acid interventions.  

### Empirical Examples  

**Human Attention Testing**:  
In a study of 25 healthy participants performing cognitive attention tasks, the system measured:  
- Average HbO increase of 0.45 ± 0.12 μM·cm during task periods  
- Corresponding CCO redox state decrease of 0.18 ± 0.05 (arbitrary units)  
- High correlation (r=0.82) with commercial fNIRS systems for HbO measurements  

**Swine Hemorrhagic Shock Experiments**:  
During controlled hemorrhage and partial REBOA interventions:  
- Detected expected HbO decreases during shock phase (ΔHbO = -1.2 μM·cm)  
- Measured CCO redox state variations correlated with treatment phases  
- Validated against arterial blood gas measurements (r=0.79 for HbO)  

These examples demonstrate the system's ability to provide clinically relevant metabolic information noninvasively. The high brightness SCL enables CCO measurements previously inaccessible to optical techniques, while the differential detection architecture provides the stability required for clinical deployment.  

The complete system offers a new capability for simultaneous hemodynamic and metabolic monitoring in critical care, neurology, and trauma applications. Future embodiments may incorporate faster wavelength selection methods (e.g., acousto-optic tunable filters) for improved temporal resolution and miniaturized designs for expanded clinical use.